RecruitingNot ApplicableNCT02743832

A Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma.

A Randomized，Multicenter，Prospectie，Controlled Clinical Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma.

Sponsor

Jinsong Hou

Enrollment

524 participants

Start Date

May 4, 2026

Study Type

INTERVENTIONAL

Conditions

Carcinoma, Squamous Cell

Summary

The purpose of this study is to determine whether cervical lymph node dissection is necessarily performed in the presence of early-stage oral squamous cell carcinoma.

Eligibility

Min Age: 20 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a procedure called Resection for primary lesion and cervical lymph node dissection and a procedure called Resection for primary lesion only for people with carcinoma, squamous cell. The study is currently recruiting participants at 1 location. People eligible for this study include aged 20 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREResection for primary lesion and cervical lymph node dissection

Resection for primary lesion and cervical lymph node dissection are performed in the early-stage oral squamous cell carcinoma.

PROCEDUREResection for primary lesion only

Only resection for primary lesion is performed in the early-stage oral squamous cell carcinoma.

Locations(1)

Guanghua School of Stomatolagy, Hospital of Stomatology Sun Yat-sen University

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02743832

Related Trials

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

NCT04892173193 locations

Intratumoral N17350 in Advanced Solid Tumors

NCT073391768 locations

Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC

NCT033704061 location

Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC

NCT045649893 locations

Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment

NCT066695721 location